- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06785012
Исследование по изучению эффективности JNJ-89495120 в лечении большого депрессивного расстройства (Moonlight-1)
Рандомизированное двойное слепое многоцентровое плацебо-контролируемое исследование для проверки концепции для оценки эффективности, безопасности и переносимости JNJ-89495120 в качестве монотерапии у взрослых участников с большим депрессивным расстройством (БДР)
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
Alabama
-
Huntsville, Alabama, Соединенные Штаты, 35801
- UAB Huntsville Regional Medical Campus
-
-
Arizona
-
Chandler, Arizona, Соединенные Штаты, 85224
- Chandler Clinical Trials
-
Phoenix, Arizona, Соединенные Штаты, 85012
- IMA Clinical Research PC Phoenix
-
Tucson, Arizona, Соединенные Штаты, 85724
- University of Arizona
-
Tucson, Arizona, Соединенные Штаты, 85704
- Noble Clinical Research
-
-
California
-
Bellflower, California, Соединенные Штаты, 90706
- CI Trials
-
Encino, California, Соединенные Штаты, 91316
- Wake Research PRI Encino
-
Garden Grove, California, Соединенные Штаты, 92844
- National Institute Of Clinical Research
-
Newport Beach, California, Соединенные Штаты, 92660
- WR-Newport Beach
-
Orange, California, Соединенные Штаты, 92866
- ATP Clinical Research
-
Redlands, California, Соединенные Штаты, 92374
- Anderson Clinical Research
-
San Diego, California, Соединенные Штаты, 92103
- Artemis Institute for Clinical Research
-
San Jose, California, Соединенные Штаты, 95124
- Lumos Clinical Research Center LLC
-
Santa Ana, California, Соединенные Штаты, 92705
- Syrentis Clinical Research
-
Temecula, California, Соединенные Штаты, 92591
- Inland Psychiatric Medical Group Inc
-
Walnut Creek, California, Соединенные Штаты, 94596
- Sunwise Clinical Research
-
-
Colorado
-
Denver, Colorado, Соединенные Штаты, 80209
- Mountain View Clinical Research
-
-
Florida
-
Fort Myers, Florida, Соединенные Штаты, 33912
- Gulfcoast Medical Research Center
-
Hollywood, Florida, Соединенные Штаты, 33021
- The Medici Medical Research
-
Homestead, Florida, Соединенные Штаты, 33030
- Advanced Research Institute of Miami
-
Maitland, Florida, Соединенные Штаты, 32751
- K2 Medical Research
-
Miami, Florida, Соединенные Штаты, 33126
- Pharmax Research Clinic Inc
-
Miami, Florida, Соединенные Штаты, 33135
- Wellness Research Center
-
Pembroke Pines, Florida, Соединенные Штаты, 33024
- Best Choice Medical and Research Service
-
Tampa, Florida, Соединенные Штаты, 33629
- Interventional Psychiatry of Tampa Bay
-
West Palm Beach, Florida, Соединенные Штаты, 33407
- Health Synergy Clinical Research
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, Соединенные Штаты, 30030
- iResearch Atlanta LLC
-
Snellville, Georgia, Соединенные Штаты, 30078
- Accelerated Clinical Research Group LLC
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60637
- University of Chicago Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46202
- Indiana University IU Health
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70115
- DelRicht Research
-
-
Maryland
-
Gaithersburg, Maryland, Соединенные Штаты, 20877
- CBH Health
-
-
Massachusetts
-
Worcester, Massachusetts, Соединенные Штаты, 01655
- University of Massachusetts Medical School
-
-
New York
-
Brooklyn, New York, Соединенные Штаты, 11229
- Integrative Clinical Trials LLC
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45219
- University of Cincinnati
-
Cincinnati, Ohio, Соединенные Штаты, 45215
- Patient Priority Clinical Sites LLC
-
Columbus, Ohio, Соединенные Штаты, 43210
- OSU Department of Psychiatry and Behavioral Health
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73116
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- University of Pennsylvania
-
-
South Carolina
-
North Charleston, South Carolina, Соединенные Штаты, 29405
- Coastal Carolina Research Center
-
-
Texas
-
McKinney, Texas, Соединенные Штаты, 75071
- Revival Research Institute LLC
-
-
Utah
-
Clinton, Utah, Соединенные Штаты, 84015
- Alpine Research Organization
-
-
Washington
-
Everett, Washington, Соединенные Штаты, 98201
- Core Clinical Research
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
- Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
- Were first diagnosed with depression before the age of 55
- Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
- Have taken 0, 1, or 2 treatments for depression in your current episode
- Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening
Exclusion Criteria:
- Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
- Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
- Post-traumatic stress disorder within the past three years of screening
- Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
- History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
- Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Arm 1: JNJ-89495120 Dose A
Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study. |
JNJ-89495120 will be administered. |
|
Экспериментальный: Arm 2: JNJ-89495120 Dose A and Dose B
Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study. |
JNJ-89495120 will be administered. |
|
Плацебо Компаратор: Arm 3: Placebo Group
Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study. |
Placebo will be administered. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
Временное ограничение: Baseline up to Day 5
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 5
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change from Baseline in MADRS Total Score to Day 2
Временное ограничение: Baseline up to Day 2
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 2
|
|
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
Временное ограничение: Baseline up to Day 2 and Day 5
|
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity. |
Baseline up to Day 2 and Day 5
|
|
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
Временное ограничение: Baseline up to Day 5
|
The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology. |
Baseline up to Day 5
|
|
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
Временное ограничение: Baseline up to Day 5
|
The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21). |
Baseline up to Day 5
|
|
Number of Participants with Adverse Events (AEs)
Временное ограничение: Up to approximately 18 weeks
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to approximately 18 weeks
|
|
Number of Participants with Abnormalities in Vital Signs Parameters
Временное ограничение: Up to approximately 18 weeks
|
Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Временное ограничение: Up to approximately 18 weeks
|
Participants with 12-lead ECG abnormalities will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants With Abnormalities in Laboratory Parameters
Временное ограничение: Up to approximately 18 weeks
|
Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
Временное ограничение: Up to approximately 18 weeks
|
Participants with changes in weight/BMI will be reported. |
Up to approximately 18 weeks
|
|
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
Временное ограничение: Up to approximately 18 weeks
|
The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline. |
Up to approximately 18 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Временное ограничение: From Baseline up to 4 weeks
|
The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials. |
From Baseline up to 4 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
Временное ограничение: From Baseline up to 4 weeks
|
The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds. |
From Baseline up to 4 weeks
|
|
Plasma Concentrations of JNJ-89495120
Временное ограничение: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
Plasma concentrations of JNJ-89495120 will be reported. |
Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
Соавторы и исследователи
Следователи
- Директор по исследованиям: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 89495120MDD2001
- 89495120MDD2001 (Другой идентификатор: Janssen Research & Development, LLC)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .